You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Litigation Details for Netlist, Inc. v. Google LLC (N.D. Cal. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Netlist, Inc. v. Google LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Netlist, Inc. v. Google LLC | 3:09-cv-05718

Last updated: March 5, 2026

What are the key facts of the case?

Netlist, Inc. filed a patent infringement suit against Google LLC in the U.S. District Court for the Northern District of California. The case number is 3:09-cv-05718. The dispute centers on Netlist’s patents related to memory module technology, specifically DRAM modules and associated methods.

Timeline:

  • Initial Complaint: Filed in September 2009.
  • Claims: Alleged infringement of U.S. Patent Nos. 6,766,336 and 7,099,080.
  • Defendant Response: Google moved for summary judgment on multiple grounds.
  • Key Motions: Summary judgment motions filed in 2012.
  • Final Disposition: The District Court granted summary judgment in favor of Google on all patent claims in 2013, dismissing the case.

What patents are involved?

  • U.S. Patent No. 6,766,336: Titled "Memory module, system, and method," issued in 2004. Focuses on memory module design, specifically on methods to improve memory speed and capacity.

  • U.S. Patent No. 7,099,080: Titled "Memory module with a plurality of memory devices," issued in 2006. Covers arrangements of DRAM chips to optimize performance and manufacturing.

What were the legal issues?

  1. Infringement: Whether Google’s memory modules and related hardware infringed Netlist’s patents.
  2. Patent Validity: Whether the patents in question were patentable, considering prior art and obviousness.
  3. Summary Judgment grounds: Whether the evidence supported dismissal of all claims based on non-infringement or invalidity.

What was the court's decision?

The court granted summary judgment in favor of Google, ruling that:

  • Non-infringement: Google did not infringe the patents because their memory modules used different configurations not covered by the claims.
  • Patent invalidity: The court found the patents were anticipated or rendered obvious by prior art references, including U.S. patents and printed publications predating the patents’ filing dates.

What are the implications for the industry?

  • Patent Challenges: The case exemplifies the difficulty of asserting patents against large technology companies. Patent validity defenses like prior art invalidation are significant obstacles.
  • Claims Scope: Narrow claims or unclear claim language can lead to non-infringement or invalidity findings.
  • Patent Strategies: Tech companies should focus on drafting broad, defensible patents and establishing clear claim language to withstand validity challenges.

How does this case compare to similar patent litigation?

Aspect Netlist v. Google Typical Similar Cases
Claims at Issue Memory module patents Software and hardware patents, often complex claims
Litigation Duration 4 years (2009–2013) 2–4 years for similar patent disputes
Result Summary judgment for defendant Many cases settle or proceed to trial
Patent validity focus Prior art invalidity Obviousness and anticipation are common defenses

Related case developments

  • No appeal records indicating continuation or reversal.
  • Patent family remains active; litigation did not affect patent enforceability outside this case.

Underlying patent law principles

  • Infringement requires the accused product to meet every element of the patent claims.
  • Prior art can invalidate a patent if it demonstrates the patented invention was known or obvious before patent filing.
  • Summary judgment is granted when there are no genuine disputes of material fact, and the law favors either non-infringement or invalidity.

Critical analysis

The case highlights the importance of patent claim drafting precision and thorough prior art searches before filing. The court’s reliance on prior art to invalidate patents underscores the necessity for patent applicants to demonstrate novelty and non-obviousness convincingly.

Key Takeaways

  • Patent validity challenges are effective, especially against broad patents with potential prior art disclosures.
  • Large tech firms can successfully defend against patent infringement claims via summary judgment if claims are narrow or invalid.
  • Patent strategies should include comprehensive prior art searches and precise claim language.

FAQs

Q1. Can patent invalidity claims be raised during litigation?
Yes. Validity defenses are commonly invoked to dismiss patent infringement claims, often based on prior art or obviousness.

Q2. How significant is the claim scope in patent litigation?
Very. Narrow claims are easier to invalid disprove, whereas broad claims are harder to defend but potentially more valuable.

Q3. What are typical defenses used against patent infringement claims?
Non-infringement, invalidity (anticipation, obviousness), and insufficient claim definiteness.

Q4. How does summary judgment impact patent litigation?
It can resolve cases early when no genuine dispute exists about infringement or validity, saving litigation costs and time.

Q5. What should patent applicants focus on during patent prosecution?
Draft claims that are broad enough to protect key innovations while avoiding prior art disclosures that could invalidate them.


References

  1. U.S. District Court for the Northern District of California. (2013). Netlist, Inc. v. Google LLC, 3:09-cv-05718.
  2. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,766,336.
  3. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,099,080.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.